Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 387,828
  • Shares Outstanding, K 94,362
  • Annual Sales, $ 20,340 K
  • Annual Income, $ -340,140 K
  • 60-Month Beta 0.94
  • Price/Sales 19.58
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade ATRA with:

Options Overview Details

View History
  • Implied Volatility 101.36% ( -20.65%)
  • Historical Volatility 97.01%
  • IV Percentile 55%
  • IV Rank 23.04%
  • IV High 255.60% on 07/11/22
  • IV Low 55.17% on 10/19/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 2,089
  • Open Int (30-Day) 3,006

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.78
  • Number of Estimates 5
  • High Estimate -0.70
  • Low Estimate -0.89
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.23 +27.24%
on 09/23/22
5.02 -18.13%
on 09/12/22
-0.18 (-4.20%)
since 09/02/22
3-Month
2.83 +45.23%
on 08/01/22
9.34 -56.00%
on 07/06/22
-4.62 (-52.92%)
since 07/05/22
52-Week
2.83 +45.23%
on 08/01/22
20.04 -79.49%
on 11/04/21
-13.37 (-76.49%)
since 10/05/21

Most Recent Stories

More News
Horizon (HZNP) Completes Enrollment in Phase IV TED Study

Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.

HZNP : 67.05 (+1.35%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

REGN : 745.68 (+0.83%)
SNY : 39.82 (-0.75%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, today announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel...

ATRA : 4.11 (-2.61%)
Merck's (MRK) Keytruda Gets Four New Approvals in Japan

The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.

MRK : 88.39 (unch)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral

Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.

EBS : 20.84 (-2.71%)
CMRX : 1.9300 (-2.03%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

ALNY : 201.02 (-0.11%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion

The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.

PCRX : 56.56 (+0.89%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.

HZNP : 67.05 (+1.35%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review

The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.

ACAD : 18.05 (-0.06%)
ATRA : 4.11 (-2.61%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.

ATRA : 4.11 (-2.61%)
ISEE : 20.99 (+6.12%)
ORIC : 3.08 (-2.22%)
ACHL : 2.32 (-2.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 4.49
2nd Resistance Point 4.35
1st Resistance Point 4.23
Last Price 4.11
1st Support Level 3.97
2nd Support Level 3.83
3rd Support Level 3.71

See More

52-Week High 20.04
Fibonacci 61.8% 13.47
Fibonacci 50% 11.44
Fibonacci 38.2% 9.40
Last Price 4.11
52-Week Low 2.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar